Exclusive Summary

• High Asset Maturity: UB430 is an Insulin Degludec biosimilar with completed Phase III clinical trials and BLA submission initiated in China, significantly de-risking development for partners.
• Global Rights Available: Unibest retains global rights, making it an ideal candidate for License-in or distribution partnerships for companies seeking to expand their metabolic portfolios.
• Proven Equivalence: Head-to-head Phase III data (N=400) confirms therapeutic compliance and safety equivalence to the reference drug (Tresiba®), ensuring strong market competitiveness.

Asset Materials

Contact Us for Full Materials